Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

56 results about "Disulphide bonds" patented technology

Disulphide bond. Definition. noun. (chemistry) (1) The single covalent bond formed from the coupling of thiol groups, especially of cysteine residues. (2) The linkage formed by the oxidation of two SH groups, each attached to a cysteine, stabilizing the structure of many protein molecules (during protein synthesis).

Cysteine-substituted RSV-f proteins

The present disclosure provides inter alia, an RSV-F protein comprising at least two mutations relative to SEQ ID NO: 1 or 3 within a region of the protein corresponding to positions 474-523 of SEQ ID NO: 1 or 3; wherein the at least two mutations introduce, through substitution or insertion, a pair of C residues into the region, which form a disulphide bond.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

A crosslinker and carbon / glass fiber-reinforced epoxy composites therefrom

PCT designated stage expiredWO2025004100A1Organic chemistryFiberPolymer science
The present invention relates to covalent network-based polymers derived from imine and disulphide based crosslinkers with the epoxy. The recyclability of the high-cost fibres is achieved by the synthesis of epoxy vitrimers based on dynamic imine and imine-disulphide bonds. Schiff base chemistry and condensation reaction are used to prepare the crosslinkers with imine linkages as well as imine-disulphide linkages. Various aromatic carbonyl compounds like divanillin, terepthaldehyde, vanillin, 4-hydroxy benzaldehyde, isatin etc. are used for the reaction with various aliphatic and aromatic amines like IPDA, 2-AFD, 4-AFD etc. The prepared epoxy vitrimers showed comparable thermal, mechanical and thermomechanical properties with the conventional DGEBA epoxy-amine system. The carbon / glass fiber-reinforced composite with the vitrimers showed superior mechanical properties beneficial for many engineering applications. The recycling of the vitrimers and composites can be achieved by simple immersion in a suitable solvent system with stirring or agitation at ambient temperature (30-60ºC) conditions. The fibers were easily recovered without losing their morphology, strength and structural integrity. With this invention, wastage of reinforcement carbon fibers and glass fibers can be minimized and the recovered fibers can be used for other applications with a circular economy approach.
Owner:COUNCIL OF SCI & IND RES

A solid phase synthesis method for polypeptides containing three pairs of disulfide bonds by introducing a pair of disulfide bonds

The present invention relates to a solid phase synthesis method for a polypeptide containing three pairs of disulfide bonds by introducing a pair of disulfide bonds, and specifically discloses the method comprising the following steps: 1) synthesizing a conjugate of a first polypeptide fragment and a solid phase synthesis resin by a solid phase synthesis method, wherein the first polypeptide fragment contains two cysteines forming a first pair of disulfide bonds; 2) removing the sulfhydryl protecting groups of the two cysteines of the first pair of disulfide bonds in the first polypeptide fragment, and oxidizing to form the first pair of disulfide bonds; 3) continuing to synthesize the remaining fragments by a solid phase synthesis method; 4) removing the sulfhydryl protecting groups of the cysteines of the third pair of disulfide bonds to form the third pair of disulfide bonds, and then removing the sulfhydryl protecting groups of the cysteine ​​of the second pair of disulfide bonds to form the second pair of disulfide bonds; 5) removing other protecting groups, cleaving the resin, and obtaining a polypeptide containing three pairs of disulfide bonds. The method of the present invention can selectively remove the protecting groups of the three pairs of polypeptides, greatly reducing the possibility of mismatching.
Owner:HYBIO PHARMA

Application of PDIL2;3 gene in regulating grain shape and chalkiness traits in rice

The application discloses application of a PDIL2;3 gene in regulation of rice grain type and chalkiness. The application provides, for the first time, important regulation of a protein disulfide isomerase coding gene PDIL2;3 on the grain type and chalkiness of rice, and a spike becomes larger, a grain becomes longer, a grain width becomes wider, the thousand-grain weight increases and the chalkiness increases by knocking out or destroying the normal expression level of the PDIL2;3 gene, so as to obtain an ideal rice grain type, improve the rice quality, provide a new approach for high-yield and high-quality breeding of rice, and have a wide application prospect.
Owner:HUBEI UNIV

Compositions comprising protein disulfide isomerase and methods of production and use thereof

Compositions are disclosed that include at least one protein disulfide isomerase or a biologically active fragment or variant thereof. Methods of producing and using the compositions are also disclosed. In particular (but not by way of limitation), methods are provided for reducing blood glucose, treating hyperglycemia, treating or reducing the occurrence of type 1 diabetes, treating or reducing the occurrence of type 2 diabetes, and / or treating or reducing the occurrence of type 3 diabetes (i.e., Alzheimer's Disease) by administering the composition that includes the at least one protein disulfide isomerase. The protein disulfide isomerase may be administered alone or may be administered simultaneously or sequentially with one or more additional active agents.
Owner:BOARD OF REGENTS FOR THE OKLAHOMA AGRI & MECHANICAL COLLEGE ACTING FOR & ON BEHALF OF OKLAHOMA STATE UNIV

A self-assembling antibacterial peptide against drug-resistant bacteria, its preparation method and application

The present invention discloses a self-assembling antibacterial peptide against drug-resistant bacteria, its preparation method and application, belonging to the field of biotechnology. It includes a branched chain A and a branched chain B. The amino acid sequence of the branched chain A is: RRRCFFF, and the amino acid sequence of the branched chain B is: FFFCRRR. The branched chain A and the branched chain B are connected by a disulfide bond formed between the thiol groups of two cysteine residues. The antibacterial peptide 3RF of the present invention self-assembles into a nanofiber structure in PB solution, and at the same time has strong antibacterial activity against drug-resistant bacteria, and the antibacterial peptide 3RF has almost no hemolytic toxicity, and has extremely high application potential in the treatment of drug-resistant bacterial infections.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Adiponectin determination kit and preparation method thereof

The invention provides an adiponectin determination kit and a preparation method thereof, the kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises a buffer solution, a preservative, a stabilizer, an unwinding agent, an anti-human adiponectin antibody and Protein; the reagent R2 comprises a buffer solution, a preservative, a stabilizer and nano microspheres. According to the kit, hexamer and multimer of adiponectin can be dissociated into trimer, the trimer is combined with a specific antibody after being captured by Protein, the antibody is connected with nano microspheres in a physical adsorption mode in the binding reaction process of the antibody and the adiponectin trimer, turbidity is formed, and then the content of total adiponectin in a sample to be detected is accurately determined. In the preparation process of the kit disclosed by the invention, the adiponectin antibody and the nano-microspheres do not need to be chemically coupled to form sensitization particles, and disulfide bonds formed between the antibody and the nano-microspheres are prevented from being dissociated by the unwinding agent, so that the use of a scavenger of the unwinding agent can be avoided, and the kit is simple and convenient to prepare.
Owner:JILIN UNIVERSITY

High-molecular polymer, preparation method thereof and application of high-molecular polymer in delivery of nucleic acid

The invention relates to the technical field of biomedical materials, in particular to a high-molecular polymer as well as a preparation method and application thereof in delivery of nucleic acid. The high-molecular polymer has a structure as shown in a formula I. The polymer has good in-vivo and in-vitro nucleic acid drug delivery performance due to good GSH responsiveness, has excellent biodegradability and small toxic and side effects, can be used as a nucleic acid drug delivery carrier, and can be rapidly degraded and release nucleic acid by taking a disulfide bond as a main chain to respond to glutathione (GSH) widely existing in cells; meanwhile, degraded small molecules can be quickly discharged out of a body and have no obvious toxicity to cells and mice. After caudal intravenous injection, the high-molecular polymer can realize spleen-targeted and lung-targeted efficient delivery of nucleic acid drugs, so that the high-molecular polymer is used as a nucleic acid drug delivery carrier to be combined with the nucleic acid drugs, and has great significance in preparation of drugs for treating genetic diseases, tumors, virus infection and other diseases.
Owner:XIAMEN UNIV

Prx5-Trx2 protein compound as well as preparation method and application thereof

The invention discloses a Prx5-Trx2 protein compound, a preparation method and application, and relates to the technical field of biology, the method comprises the following steps: mutating cysteine of cysteine residue C47 in Prx5 into serine to obtain a Prx5C47S mutant, and preparing Prx5C47S mutant protein; the method comprises the following steps: mutating cysteine of a cysteine residue C34 in Trx2 into serine, so as to obtain a Trx2C34S mutant; the preparation method comprises the following steps: preparing Trx2C34S mutant protein; the Prx5C47S mutant protein and the Trx2C34S mutant protein are subjected to a disulfide bond cross-linking reaction, and the Prx5-Trx2 protein compound is prepared. According to the invention, a large amount of stable Prx5-Trx2 protein compounds can be prepared, and a basis is provided for research and development of novel anti-tumor drug-resistant drugs targeting the Prx5-Trx2 protein compounds.
Owner:JINING MEDICAL UNIV

Mass spectrometry kit including a cross-linked antibody or fragment thereof

An anti-immunoglobulin specific antibody (or fragment thereof), characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the antibody or fragment thereof. A method purifying an anti-immunoglobulin specific antibody (or fragment thereof), characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the antibody or fragment thereof. A method of quantifying an amount of a subject analyte, or a fragment of an analyte in a sample from the subject comprising: (i) adding to the sample a predetermined amount of one or more control analytes or fragments thereof, which are distinguishable from the equivalent subject analyte or fragment; (ii) measuring the relative amount of the subject analyte or fragment and the amount of the control analyte or fragment in the sample; and (iii) comparing the relative amount of subject analyte or fragment to the relative amount of control analyte or fragment, to quantify the amount of analyte or fragment in the original subject sample.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH +1

Modified binding proteins and therapeutic uses thereof

The present invention relates to modified T cell receptors and their uses in treating various diseases or conditions, particularly cancer and autoimmune diseases. A binding protein comprising a variable domain comprising a complementarity-determining region (CDR) capable of contacting a peptide bound to an HLA molecule, wherein the CDR 5 comprises a cysteine capable of forming a disulphide bond with a cysteine in the peptide bound to the HLA molecule, typically wherein the cysteine is introduced into the CDR by mutation or modification of an existing residue.
Owner:MONASH UNIV +1

Vaccine compositions, methods, and uses thereof

PendingCN122356309ARabiesRecombinant peptide
The present invention provides vaccine compositions, methods and uses thereof, the vaccine compositions are immunogenic compositions of secreted fusion proteins, wherein the secreted fusion proteins comprise a rabies or soluble influenza virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against rabies or influenza infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment and / or diagnosis and related kits.
Owner:SICHUAN CLOVER BIOPHARM INC

Endometriosis biomarkers

ActiveUS12674806B2ZymogenSelenoprotein P
A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from Table 1, 2 or 3 in a sample from a subject, where in the at least one protein may be selected from the list comprising: Beta-Ala-His dipeptidase, Apolipoprotein L1, Methanethiol oxidase, Vitamin K-dependent protein S, von Willebrand factor, Plasminogen, Selenoprotein P, Protein disulfide-isomerase A6 and Inter-alpha-trypsin inhibitor heavy chain H3, and (b) using the expression level to determine whether the subject has endometriosis.
Owner:PROTEOMICS INT (IP) PTY LTD

A class of peptides and their corresponding drug / fluorescent dye conjugates for targeted cancer therapy

This invention discloses a novel class of peptides for targeted cancer therapy and their corresponding drug or fluorescent dye conjugates, belonging to the field of biomedical technology. These peptides are designed based on the optimized structure of natural LHRH-III, enabling them to specifically bind to and efficiently internalize into tumor cells overexpressing luteinizing hormone-releasing hormone receptor (LHRH-R). After fluorescent conjugation, their targeting ability against 4T1 cells is comparable to that of the classic peptide [D-Lys]. 6 The [-LHRH-I] peptide exhibits comparable to or superior performance and significantly improves cellular internalization efficiency. In vivo distribution studies have shown that its liver accumulation is significantly reduced compared to the control group, effectively lowering the risk of hepatotoxicity. Furthermore, by conjugating the targeting peptide with antitumor drugs (such as camptothecin or doxorubicin) via disulfide linkers, the resulting peptide-drug conjugates (PDCs) demonstrate excellent responsive drug release characteristics and good in vitro and in vivo antitumor activity. The peptides and conjugates provided by this invention have potential application value in cancer targeted therapy and diagnosis with high specificity and low toxicity.
Owner:BEIJING UNIV OF CHEM TECH

Methods to prevent disulfide scrambling for MS-based proteomics

The present invention generally pertains to methods of preventing disulfide scrambling in non-reducing liquid chromatography-mass spectrometry analysis of a protein of interest. In particular, the present invention pertains to the addition of maleimide to a non-reducing liquid chromatography-mass spectrometry analysis of a protein to prevent disulfide scrambling.
Owner:REGENERON PHARMACEUTICALS INC

Cyclic antibacterial peptide CycP-1 targeting multi-drug-resistant klebsiella pneumoniae, and composition and application of cyclic antibacterial peptide CycP-1

The invention belongs to the technical field of biological medicines, and discloses a cyclized antibacterial peptide CycP-1 targeting multiple drug-resistant klebsiella pneumoniae, and a composition and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1, cysteine residues at the first site and the 24th site in a molecule of the antibacterial peptide form a disulfide bond, and the antibacterial peptide is in cyclization conformation and shows good in-vitro protease stability. Experiments show that the antibacterial peptide has a remarkable inhibiting effect on multi-drug-resistant and pan-drug-resistant klebsiella pneumoniae, and when the antibacterial peptide is combined with antibiotics, the antibacterial effect can be enhanced, drug resistance can be reversed or reduced, and generation of drug resistance can be delayed. A mouse pneumonia model in-vivo experiment further proves that after oral administration of the antibacterial peptide, the lung tissue bacterial load of a pan-drug resistant klebsiella pneumonia infected mouse can be remarkably reduced, lung pathological injury is relieved, the survival rate of the infected mouse is remarkably increased, and the effect is better when the antibacterial peptide is combined with polymyxin B.
Owner:湖北江夏实验室 +1

Macrocyclic peptide libraries displayed on surface of yeast cells

The present invention relates to the generation of a library of cysteine-enriched macrocyclic peptide sequences expressed on the surface of yeast cells, methods for their preparation and a population of yeast cells genetically modified to express a plurality of disulfide tethered macrocyclic peptide ligands having different structures and amino acid sequences on the surface of yeast cells.
Owner:ALZANIA LTD

Double-target cyclic peptide as well as synthesis method and medical application thereof

The invention discloses a double-target-point cyclic peptide and a synthesis method and medical application thereof.The amino acid sequence of the double-target-point cyclic peptide is Cys-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Alaa-Cys-Lys-Pro-Ser-Trp-Arg-Alaa-Asp, Cys1 and Cys10 form a cyclic peptide structure through disulfide bond cyclization, the relative positions of the N terminal and the C terminal are stabilized, the enzyme resistance and the structural stability are improved, and the double-target-point cyclic peptide has the advantages that the double-target-point cyclic peptide is obtained; further, protease degradation is resisted, the half-life period is prolonged, and efficient analgesia is realized by synergistically activating a mu opioid receptor and inhibiting a voltage-gated sodium ion channel 1.8. The double-target cyclopeptide designed by the invention has the beneficial characteristics of simple structure, convenience in artificial synthesis, low production cost and the like, and has huge medical industrial applicability.
Owner:XINXIANG MEDICAL UNIV

Native delivery of biomolecules into plant cells using ionic complexes with cell-penetrating peptides

The invention relates to a complex comprising a first component: (i) a carrier peptide comprising a cell-penetrating sequence and a polycation sequence: and a second component (ii) a ribonucleic acid (RNA), PNA and / or protein, wherein the carrier peptide is a cyclic peptide comprising at least 2 cysteine residues bridged by a disulphide bond.
Owner:BASF PLANT SCI GMBH +1

Co-delivery system

PCT designated stage expiredWO2025099252A1Hybrid immunoglobulinsDisulphide bondsDelivery system
The present invention relates to a co-delivery system comprising one or more nucleic acids encoding a first antibody and a second antibody. In particular, the co-delivery system encodes a first antibody and a second antibody each comprising two antibody chains, and wherein the two antibody chains of each antibody are covalently linked by at least one inter-chain disulphide bond located at a different position in each of the two antibodies. The invention also relates to a vector comprising the co-delivery system, a nucleic acid particle comprising the co-delivery system and a composition comprising the co-delivery system as well as uses of the co-delivery system in a method of therapy and / or a diagnostic method.
Owner:BIONTECH SE

Lanthanide-templated protein dimerization and finer rare earth separation

Provided are proteins and peptides suitable for binding lanthanide ions and / or actinide ions. Proteins of the present disclosure may contain or be one of the following sequences: DDKAACAX1GIAAVKAX2VEKLAPEAVPQKLKRALKIAEREQGEGX 3FX4X5CLX6ALX7DAKRALPKX8X9 (SEQ ID NO:1) or MMRTRTSLAVPRGFRGSALLADDKAACAX1GIAAVKAX2VEKLA-PEAVPQKLKRALKIAEREQGEGX3FX4X5CLX6ALX7DAKRALPKX8X9 (SEQ ID NO:52), where X1 is D or S; X2 is R or K; X3 is E, Q, or M; X4 is D, N, Q, or K; X5 E, N, Q, D, A, or T; X6 is E, A, or Q; X7 is D or E; X8 is Y, W, or absent; and X9 is G or absent, or a protein having at least 70% identity to SEQ ID NO:1 or 52. Proteins or peptides of the present disclosure may contain a metal-binding motif or be REX1X2EX3EX4DEC (SEQ ID NO:53), where X1 is any amino acid; X2 is any amino acid, (e.g., G, A, K, R); X3 is any amino acid, (e.g., G, A, or K); and X4 is F or Y; and the C forms a disulfide bond with another cysteine residue elsewhere in the peptide. Also provided are methods of using any one of the proteins or peptides, methods of making any one of the proteins or peptides, and kits.
Owner:THE PENN STATE RES FOUND INC

Methods of producing two chain proteins in prokaryotic host cells

Provided herein are methods and host cells for producing a polypeptide containing two chains, such as an antibody, half-antibody, antibody fragment, or one-armed antibody. The methods and host cells allow for two-chain polypeptide production using expression of polynucleotides encoding the polypeptide chains from extra-chromosomal polynucleotide(s), and expression of one or more chaperone protein(s) (e.g., peptidyl-prolyl isomerases and / or protein disulfide oxidoreductases) from the host cell chromosome using non-native combination(s) of promoters and translational units encoding a chaperone protein.
Owner:GENENTECH INC

Late-stage peptide cyclization for disulfide mimetic formation

This invention discloses a method for constructing disulfide mimetic compounds for late cyclization of peptides. The disclosed method provides late cyclization via thioacetalization of peptides containing two cysteine ​​residues to form a thioacetal group. These bonds are stable under acidic, basic, and reducing conditions. A wide range of cyclic ketones, and even acetone, can be used as crosslinking agents in this reaction. Since trifluoroacetic acid (TFA) can function as both a catalyst and the sole solvent, most peptide sequences can be cyclized by the disclosed method. The disclosed method offers many advantages and merits, including the use of TFA as a robust catalyst and the sole required solvent, the readily available availability of acetone and a variety of cyclic ketones as reactants, good chemoselectivity and tolerance of natural peptides to this reaction, and the fact that the resulting crosslinks are structural mimetic compounds of disulfides.
Owner:VERSITECH LTD

Self-assembled antibacterial peptide for resisting drug-resistant bacteria as well as preparation method and application of self-assembled antibacterial peptide

The invention discloses a self-assembled antibacterial peptide for resisting drug-resistant bacteria as well as a preparation method and application of the self-assembled antibacterial peptide, and belongs to the technical field of biology. Comprising a branched chain A and a branched chain B, the amino acid sequence of the branched chain A is RRRCFFF, the amino acid sequence of the branched chain B is FFFCRRR, and the branched chain A and the branched chain B are connected through a disulfide bond formed between thiol groups in two cysteine residues. The antibacterial peptide 3RF disclosed by the invention is self-assembled into a nanofiber structure in a PB solution, has strong antibacterial activity on drug-resistant bacteria, almost has no hemolytic toxicity, and has extremely high application potential in the aspect of treating infection caused by the drug-resistant bacteria.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Disulfide-containing lipid molecules for mRNA delivery and methods of making and uses thereof

The application discloses a disulfide-containing lipid molecule for mRNA delivery and a preparation method and application thereof, and a synthesis method of the lipid molecule is as follows: 2,2-dithiodiethanol diacrylate is used as a raw material, and is further reacted with selected hydrophilic amines to generate an intermediate, and the intermediate is further reacted with hydrophobic amines to obtain a final lipid molecule for delivering mRNA, wherein the hydrophilic amine raw material is one of 4A1, 4A2 and 4A3; the hydrophobic amine raw material is one of C18, 2C8 and 2C10; the prepared lipid molecule contains a head group generating a cation by ionization, and nucleic acids carry a negative charge, so that the two can be efficiently combined, thereby significantly improving the loading rate of nucleic acids. And the carbon chain length and the number of branches of the hydrophobic alkane chain have a crucial influence on the stability of the formed nanoparticles, so that the lipid molecule has a good prospect in the application of delivering mRNA molecules.
Owner:ZHEJIANG UNIV OF TECH

Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists

PendingJP2025186365AAntipyreticAnalgesicsIntegrin antagonistOral medication
To provide a method for treating inflammatory bowel disease (IBD).SOLUTION: The present invention relates to methods of treating inflammatory bowel diseases, including with engineered peptides (e.g. peptide monomers and dimers comprising disulfide or thioether intramolecular bonds) that bind α4β7 integrin. In one aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering to the subject an α4β7 integrin antagonist, wherein the antagonist is administered to the patient orally at a dose of about 100 mg to about 500 mg, once or twice daily, wherein the antagonist is a peptide dimer compound comprising two peptides, or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: Figure 22
Owner:PROTAGONIST THERAPEUTICS INC

Bioavailable protein disulfide isomerase inhibitors

Compounds according to formula (I) are described wherein R1 is an amino acid or a modified amino acid linked to the compound through a peptide bond, R2 is selected from CN, SO2CH3, NO2, CO2R3, CONHR3, NH2, NMe2 and CF3, and R3 is selected from H or lower alkyl, X is O or S, and Y is C—H or N, or a pharmaceutically acceptable salt thereof. The compounds can be used as protein disulfide isomerase inhibitors. The compounds can also be used in a method of treating or cancer in a subject.
Owner:THE CLEVELAND CLINIC FOUND